GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies

被引：0

作者：

Hong, Rebecca ^{[1
]}

Edgar, Kyle ^{[1
]}

Song, Kyung ^{[1
]}

Steven, Schmidt ^{[1
]}

Young, Amy ^{[1
]}

Hamilton, Patricia ^{[1
]}

Arrazate, Alfonso ^{[1
]}

De La Cruz, Cecile ^{[1
]}

Chan, Connie ^{[1
]}

Pang, Jodie ^{[1
]}

Salphati, Laurent ^{[1
]}

Belvin, Marcia ^{[1
]}

Nannini, Michelle ^{[1
]}

Staben, Steven ^{[1
]}

Friedman, Lori ^{[1
]}

Sampath, Deepak ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PD4-14

引用

页数：1

共 50 条

[1] GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
Edgar, Kyle
Hong, Rebecca
Song, Kyung
Schmidt, Steven
Hafner, Marc
Arrazate, Alfonso
Williams, Erin
De La Cruz, Cecile
Oeh, Jason
Sampath, Deepak
Staben, Steve
Friedman, Lori
[J]. CANCER RESEARCH, 2020, 80 (04)
[2] PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS
Pang, Jodie
Baumgardner, Matthew
Braun, Marie-Gabrielle
Cheong, Jonathan
Edgar, Kyle
Friedman, Lori
Hanan, Emily
Jaochico, Allan
Ma, Shuguang
Plise, Emile
Schmidt, Stephen
Liu, Ning
Song, Kyung
Staben, Steve
Salphati, Laurent
[J]. DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S37 - S37
[3] RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
Pazolli, Ermira
Kipp, Randy
Boezio, Alessandro
Gunaydin, Hakan
Iskandar, Amanda
Zubrowski, Matthew
Williams, Bret
Shortsleeves, Kelley
Larivee, Alexandre
McLean, Tom
Michelsen, Klaus
Zeng, Hongtao
LaRochelle, Jonathan
Manna, Joe
DiPietro, Lucian
Lescarbeau, Andre
Mader, Mary
Bennet, Bindu
Wilbur, Jeremy
Wang, Qi
Pierce, Levi
Martin, Iain
Watters, James
Fortin, Pascal
Bergstrom, Donald
[J]. CANCER RESEARCH, 2022, 82 (04)
[4] OKI-219, a PI3KaH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in preclinical PI3KaH1047R mutant breast cancer models
Taylor, Molly A.
Zhao, Qian
Mareska, David
Hoh, Maria
Izrayelit, Yevgeniy
Litwiler, Kevin
Boys, Mark L.
Woessner, Rich
Walker, Duncan
Winkler, James D.
Diamond, Jennifer
[J]. CANCER RESEARCH, 2024, 84 (09)
[5] Determination of the PI3Kα selective inhibitor alpelisib mechanism of action and efficacy in ER+/ PIK3CA mutant breast cancer preclinical models
Fritsch, Christine
Pfister, Estelle
Ebel, Nicolas
Guthy, Daniel
Schnell, Christian
Hofmann, Francesco
[J]. CANCER RESEARCH, 2018, 78 (13)
[6] A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2-breast cancer
Jhaveri, Komal
Kalinsky, Kevin
Bedard, Philippe
Cervantes, Andres
Saura, Cristina
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Gambardella, Valentina
Veitch, Zachary
Oliveira, Mafalda
Dickmann, Leslie
Kotani, Naoki
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Juric, Dejan
[J]. CANCER RESEARCH, 2020, 80 (04)
[7] A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors
Juric, Dejan
Kalinsky, Kevin
Oliveira, Mafalda
Cervantes, Andres
Bedard, Philippe
Krop, Ian
Hamilton, Erika
Schmid, Peter
Varga, Andrea
Turner, Nick
Italiano, Antoine
Saura, Cristina
Gambardella, Valentina
Veitch, Zachary
Dickmann, Leslie
Kotani, Naoki
Fredrickson, Jill
Kapp, Amy
Hutchinson, Katie
Royer-Joo, Stephanie
Vaze, Anjali
Schutzman, Jennifer
Jhaveri, Komal
[J]. CANCER RESEARCH, 2020, 80 (04)
[8] The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models
Sampath, D.
Nannini, M. A.
Jane, G.
Hong, R.
Parsons, K. L.
Belvin, M.
Friedman, L. S.
Wallin, J. J.
[J]. CANCER RESEARCH, 2013, 73
[9] The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action
Edgar, Kyle A.
Song, Kyung
Schmidt, Stephen
Kirkpatrick, Don
Phu, Lilian
Nannini, Michelle
Hong, Rebecca
Cheng, Eric
Young, Amy
Sampath, Deepak
Friedman, Lori S.
[J]. CANCER RESEARCH, 2016, 76
[10] More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro
Zheng, Jie
Wang, Huan
Yao, Jia
Zou, Xianjin
[J]. PHARMAZIE, 2014, 69 (01): : 38 - 42

← 1 2 3 4 5 →